A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata

    July 2026 in “ Advances in Therapy ”
    J.Q. Del Rosso, Pariser Dm, Neal Bhatia … Thomas J. Ferro
    Studysummary This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Patient Preferences in the Treatment of Alopecia Areata: A Review of the Literature JAAD reviews. · 2024
    2. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    3. Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment Journal of dermatology · 2023
    4. The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata Dermatology and Therapy · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Factors Influencing Alopecia Areata Treatment Decisions: A Qualitative Assessment JAAD International · 2022
    7. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    8. Alopecia Areata: A Comprehensive Review of Pathogenesis and Management Clinical Reviews in Allergy & Immunology · 2017